News | April 01, 2025
Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
AstraZeneca Pharma India discontinues manufacturing of Imdur
AstraZeneca Pharma India discontinues manufacturing of Imdur
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Subscribe To Our Newsletter & Stay Updated
